P
Pyxis Oncology, Inc. (PYXS)
NMS – Real vaqt narxi. Valyuta: USD
2.60
-0.15 (-5.45%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
2.60
-0.15 (-5.45%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Pyxis Oncology, Inc., klinik bosqichdagi kompaniya bo'lib, qattiq o'smalarni davolash uchun terapevtik vositalarni ishlab chiqish bilan shug'ullanadi. Uning yetakchi antitel-dorilari (ADC) mahsulot nomzodi PYX-201 hisoblanadi, bu inson immunoglobulin G1 (IgG1) dan iborat eksperimental yangi ADC bo'lib, u takroriy yoki refrakter qattiq o'smalarga chalingan bemorlarni davolash uchun 1-bosqich klinik sinovda; PYX-102, T-hujayralari va NK-hujayralaridagi ingibitsion retseptor KLRG1 ga yo'naltirilgan eksperimental immunoterapiya, monoterapiya yoki kombinatsiyalangan davolash sifatida ishlatish potentsialiga ega; va yetakchi immuno-onkologiya (IO) mahsuloti nomzodi PYX-106, Siglec-15 ga yo'naltirilgan eksperimental to'liq inson IgG1 antitelasi bo'lib, u rivojlangan qattiq o'smalarga chalingan bemorlarni davolash uchun 1-bosqich klinik sinovda. Kompaniya, shuningdek, turli xil saraton kasalliklari ko'rsatkichlari bo'lgan bemorlarda rakka qarshi faolligi isbotlangan CD40 agonisti bo'lgan PYX-107ni ishlab chiqmoqda, u yumshoq to'qimalarning sarkomalari, kengaygan va gastroezofageal birikmalar, saraton kasalliklari va oshqozon osti bezi kanalining adenokarsinomasi kabi o'smalarni davolash uchun 2-bosqich klinik sinovda. U Pfizer Inc. bilan micvotabart pelidotin va PYX-203, shu jumladan ADC mahsulot nomzodlarini ishlab chiqish va tijoratlashtirish, shuningdek, litsenziyalangan maqsadlarga yo'naltirilgan boshqa ADC mahsulot nomzodlari uchun litsenziyalash shartnomasiga ega; va Biosion USA, Inc. bilan IO mahsuloti nomzodi PYX-106ni ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha shartnomaga ega. Pyxis Oncology, Inc. 2018 yilda tashkil etilgan va shtab-kvartirasi Bostonda, Massachusets shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Donna Regalado | Head of Human Resources |
| Dr. Balu N. Balasubramanian Ph.D. | Interim Chief Technology Officer |
| Dr. Charles T. Gombar Ph.D. | Senior Vice President of Portfolio & Program Management |
| Dr. Hongwei Wang M.D., Ph.D. | Head of ADC Development & Clinical Strategy |
| Dr. Michael Bui | Head of Global Regulatory Affairs |
| Dr. Shui He Ph.D. | Head of Biometrics |
| Dr. Supriya Roth Ph.D. | Head of Commercial Development |
| Mr. Alex Kane M.B.A. | Senior Vice President of Investor Relations & Capital Markets |
| Mr. Thomas Civik | Interim CEO & Director |
| Ms. Marsha Crochiere Ph.D. | Head of Translational Medicine & Research |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | 8-K/A | pyxs-20260206.htm |
| 2026-03-23 | 8-K | pyxs-20260323.htm |
| 2026-03-23 | 10-K | pyxs-20251231.htm |
| 2026-02-06 | 8-K | pyxs-20260206.htm |
| 2025-12-18 | 8-K | pyxs-20251218.htm |
| 2025-12-08 | CORRESP | filename1.htm |
| 2025-11-26 | S-3 | pyxs20251125_s3.htm |
| 2025-11-03 | 8-K | pyxs-20251103.htm |
| 2025-11-03 | 10-Q | pyxs-20250930.htm |
| 2025-08-14 | 10-Q | pyxs-20250630.htm |